November 19, 2019

Emily M. Leproust, Ph.D.
President, Chief Executive Officer and Director
Twist Bioscience Corp
681 Gateway Blvd.
South San Francisco, CA 94080

       Re: Twist Bioscience Corp
           Registration Statement on Form S-3
           Filed November 6, 2019
           File No. 333-234538

Dear Dr. Leproust:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to the comment, we may have additional comments.

Registration Statement on Form S-3

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and
Bylaws, page 6

1.     We note that your forum selection provision identifies the Court of
Chancery of the State
       of Delaware as the exclusive forum for certain litigation, including any
"derivative
       action." Please disclose whether this provision applies to actions
arising under
       the Exchange Act. In that regard, we note that Section 27 of the
Exchange Act creates
       exclusive federal jurisdiction over all suits brought to enforce any
duty or liability created
       by the Exchange Act or the rules and regulations thereunder. If this
provision does not
       apply to actions arising under the Exchange Act, please also ensure that
the exclusive
       forum provision in the governing documents states this clearly, or tell
us how you will
       inform investors in future filings that the provision does not apply to
any actions arising
       under the Exchange Act. We also note that your forum selection provision
identifies the
       federal district courts of the United States of America as the exclusive
forum for resolving
 Emily M. Leproust, Ph.D.
Twist Bioscience Corp
November 19, 2019
Page 2
      any complaint asserting a cause of action arising under the Securities
Act. We note that
      Section 22 of the Securities Act creates concurrent jurisdiction for
federal and state courts
      over all suits brought to enforce any duty or liability created by the
Securities Act or the
      rules and regulations thereunder. Please revise your prospectus to
specifically state that
      there is uncertainty as to whether a court would enforce such provision
and that investors
      cannot waive compliance with the federal securities laws and the rules
and regulations
      thereunder.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Chris Edwards at (202) 551-6761 or Irene Paik at (202)
551-6553 with any
other questions.



                                                             Sincerely,
FirstName LastNameEmily M. Leproust, Ph.D.
                                                             Division of
Corporation Finance
Comapany NameTwist Bioscience Corp
                                                             Office of Life
Sciences
November 19, 2019 Page 2
cc:       Andrew D. Thorpe, Esq.
FirstName LastName